Author Archives: Hayashi

We discovered KLF4 variants which accelerate and stabilize reprogramming to pluripotency. Borisova E, Nishimura K, An Y, Takami M, Li J, Song D, Matsuo-Takasaki M, Luijkx D, Aizawa S, Kuno A, Sugihara E, Sato T, Yumoto F, Terada T, Hisatake K, Hayashi Y. Structurally-discovered KLF4 variants accelerate and stabilize reprogramming to pluripotency. iScience. 2021 Dec 21:103525. doi.org/10.1016/j.isci.2021.103525 Our study demonstrates how modifications in amino acid residues of DNA-binding domains enable next-generation reprogramming technology with engineered reprogramming factors.

We have published a research article on the generation and characterization of iPS cell lines with deleted JAG1 gene by genome editing technology. Song D, Zheng YW, Hemmi Y, An Y, Noguchi M, Nakamura Y, Oda T, Hayashi Y.Generation of human induced pluripotent stem cell lines carrying homozygous JAG1deletions. Stem Cell Res. 2021 Oct 26;57:102588. doi: 10.1016/j.scr.2021.102588.Epub ahead of print. PMID: 34736037. I’d like to thank all the co-authors.Congratulations, Song-san!

A postdoctoral fellow, Dr. Hidernori Ito, has joined our team.Welcome aboard, Ito-san! He studied vasculogenesis using mouse ES cell-derived cells and leukemia model mice previously.I hope he will carry out excellent studies here!

We have published a research article on the generation and characterization of iPS cell lines with fluorescent protein with ISL1 expression. Tsukamoto S, Nakade K, Wakabayashi T, Nakashima K, Takami M, Hemmi Y, Kuramochi Y, Shimizu T, Arai Y, Matsuo-Takasaki M, Noguchi M, Nakamura Y, Miwa Y, Hayashi Y. Generation of two ISL1-tdTomato reporter human induced pluripotent stem cell lines using CRISPR-Cas9 genome editing. Stem Cell Res. 2021 May;53:102363. doi: 10.1016/j.scr.2021.102363. Epub 2021 Apr 22. PMID: 34087992. I’d like to thank all the co-authors.Congratulations, Tsukamoto-san! We’re aiming to use these iPS cells to develop cellular assays to monitor ISL1 expression.

We have published a research article on the generation and characterization of iPS cells from adrenoleukodystrophy patients. Kuramochi Y, Awaya T, Matsuo-Takasaki M, Takami M, An Y, Li J, Hemmi Y, Wakabayashi T, Arai Y, Inoue J, Noguchi M, Nakamura Y, Asaka I, Akimoto K, Saito MK, Hayashi Y. Generation of two human induced pluripotent stem cell lines derived from two X-linked adrenoleukodystrophy patients with ABCD1 mutations. Stem Cell Res. 2021 May;53:102337. doi: 10.1016/j.scr.2021.102337. Epub 2021 Apr PMID: 33901816. I’d like to thank all the co-authors.Congratulations, Kuramochi-kun! We’re aiming to use these iPS cells to develop disease models and new therapies of adrenoleukodystrophy!

We have published a review article about “Studying Abnormal Chromosomal Diseases Using Patient-Derived Induced Pluripotent Stem Cells” in Frontiers in Cellular Neuroscience. Hayashi Y, Takami M, Matsuo-Takasaki M. Studying Abnormal Chromosomal Diseases Using Patient-Derived Induced Pluripotent Stem Cells. Front Cell Neurosci. 2020;14:224. Published 2020 Aug 13. doi:10.3389/fncel.2020.00224

Two new undergraduate student trainees has been joined from the pharmaceutical department of Tokyo University of Science. Let’s do the best science together!

We have published a research article on the generation and characterization of iPS cells from patient cells of genetic kidney disease. Arai Y, Takami M, An Y, Matsuo-Takasaki M, Hemmi Y, Wakabayashi T, Inoue J, Noguchi M, Nakamura Y, Sugimoto K, Takemura T, Okita K, Osafune K, Takasato M, Hayata T, Hayashi Y.Generation of two human induced pluripotent stem cell lines derived from two juvenile nephronophthisis patients with NPHP1 deletion.Stem Cell Res. 2020 May;45:101815. doi: 10.1016/j.scr.2020.101815. Epub 2020 Apr 21. PMID: 32361464 I’d like to thank all the co-authors.Congratulations, Arai-kun! We’re aiming to use these iPS cells to develop disease models and new therapies of nephronophthisis !

RIKEN’s International Program Associate (IPA) is a non-Japanese doctoral candidate attending a Japanese or overseas graduate school participating in RIKEN’s joint graduate school program. IPAs conduct research at RIKEN under the supervision of RIKEN scientists as part of work toward obtaining a PhD. RIKEN’s joint graduate school program is based on agreements with a number of Japanese and overseas universities and aims to identify and foster talented young scientists capable of contributing to the advancement of science for the global community.https://www.riken.jp/en/careers/programs/ipa/index.html Now, we’re recruiting IPA during this October to next March.The deadline is April 30. If you’re eligible and interested in our lab,please let me know by an email.

By the end of March, we had 4 lab members left our lab. One undergraduate trainee goes on to public graduate school in Tokyo.Two master program trainees join a Japanese big cosmetic company and an international pharmaceutical company.One technical staff joins our collaborative startup company in Tokyo. I really congratulate them and wish for their future success.